The Salt Lake City-based firm said that it expects to report fourth-quarter molecular diagnostic revenues of $86 million. Analysts, on average, were expecting revenues of $91.6 million for the quarter ended June 30.
The partners are deciding whether to run the multiplex test on a microarray or a sequencing platform. Factors in the decision include the complexity of the test and the technical feasibility of multiplexed, targeted resequencing.
On its website, the company informs customers that its service tests for the i4000377, i4000378, and i4000379 SNPs in BRCA1 and BRCA2 genes, either one of which may “influence your carrier status for breast/ovarian cancer.”